← Leaderboards
Mark Louis Heiman
Monon Bioventures, Llc
$1,298,023
Attributed
$1,298,023
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $504.8K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,298,023 · 1
By mechanism
R44$1,298,023 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Emergency Department Visit”
- Xinhua Li · Nano Terra, Inc.$24,223,911
- Abraham Aizer Brody · New York University School Of Medicine$18,899,006
- Stacy Ann Sterling · Kaiser Foundation Research Institute$10,315,890
- Katharina Schultebraucks · New York University School Of Medicine$6,916,506
- Ewa Karina Czyz · University Of Michigan At Ann Arbor$6,714,315
- Theron C Casper · Utah State Higher Education System--University Of Utah$6,360,209
Research focus
Emergency Department VisitAmyloid Fibril FormationAdverse EventAnalytical MethodAntibodiesAntibody ResponseAmericanBlood GlucoseCessation Of LifeChargeCleaved CellCommercializationComplexCostArtificial PancreasAmyloid FibrilsDiabetes MellitusDiabeticDiabetic ComaDoseDropsDrug KineticsEffectivenessEmergency Situation
Grant awards (3)
Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$504,770
R44 · FY2021 · DK · contact PI
Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$495,101
R44 · FY2020 · DK · contact PI
Soluble, solution-stable phospho-glucagon for hypoglycemic rescue$298,152
R44 · FY2019 · DK · contact PI